

# Neuroendocrine Tumor

## - A multidisciplinary discussion

11-Nov-2017, Saturday 09:00-17:30

Taipei Marriott Hotel

No. 199 Lequn 2nd Road, Zhong Shan District, Taipei, Taiwan  
台北市中山區樂群 2 路 199 號

Time	Topic	Presenter	Moderator
09:00-09:30	<b>Endoscopy</b> Recent development in NET management by endoscopic techniques	Dr. Hsiu-Po Wang 王秀伯	Dr. Chao-Hung Kuo 郭昭宏
09:30-09:40	Q&A		
09:40-10:10	<b>Endocrinology</b> Management of functional NET	Dr. Jin-Ying Lu 呂金盈	Dr. Tien-Chun Chang 張天鈞
10:10-10:20	Q&A		
10:20-10:40	<b>Break</b>		
10:40-11:10	<b>Chest medicine</b> Diagnosis and treatment of lung neuroendocrine tumor	Dr. Shinn-Liang Lai 賴信良	Dr. Yuh-Min Chen 陳育民
11:10-11:20	Q & A		
11:20-11:50	<b>Pathology</b> Evolution of NET: History and classification	Dr. Chin-Yuan Tzen 曾嶽元	Dr. Chiung-Ru Lai 賴瓊如
11:50-12:00	Q&A		
12:00-13:30	<b>Lunch</b>		
13:30-14:10	<b>Nuclear Medicine</b> - Imaging of NET - Recent development in Peptide Receptor Radionuclide Therapy	Dr. Sean X. Yan 顏學先	Dr. Ming-Huang Chen 陳明晃
14:10-14:20	Q&A		
14:20-14:50	<b>Surgery</b> Recent advance in surgical management of NET	Dr. Yan-Shen Shan 沈延盛	Dr. Chun-Nan Yeh 葉俊男
14:50-15:00	Q&A		
15:00-15:20	<b>Break</b>		

15:20-15:50	<b>Genetics</b> Genetic basis of differential response to everolimus between East and West	Dr. Wen-Chi Chou 周文其	Dr. Chia-Jui Yen 顏家瑞
15:50-16:00	Q&A		
16:00-16:50	<b>Medical Oncology</b> Recent development of immunotherapy in NET	Dr. James Yao	Dr. Li-Tzong Chen 陳立宗
16:50-17:00	Q&A		
17:00-17:30	<b>Panel Discussion</b> <ul style="list-style-type: none"> <li>Does new WHO pNET classification affect treatment choice?</li> <li>Is liver transplantation and primary tumor resection beneficial?</li> <li>Is resection of G3 NET in the elderly beneficial?</li> <li>Is it possible for typical and atypical carcinoma to become large cell and small cell lung carcinoma?</li> <li>What is the cell origin of MANEC?</li> </ul>	All speakers	Dr. Li-Tzong Chen 陳立宗

**醫師介紹...**
*Doctors Intro*

心臟血管科  
 胃腸肝膽科  
 胸腔科  
 代謝內分泌  
 感染科  
 風濕免疫科  
 腎臟科  
 血液腫瘤科  
 一般內科

內科部簡介

次專科介紹


醫師介紹

研究成果

醫學教育

## → 個人專長：

- 內科學
- 消化醫學
- 急診醫學及重症醫學
- 胃鏡大腸鏡
- 小腸疾病及小腸鏡
- 膠囊內視鏡
- 消化道腫瘤內視鏡切除術
- 特殊光學內視鏡術
- 消化道止血術
- 消化道狹窄內視鏡擴張術
- 消化道支架置放術(食道、胃、十二指腸、大腸)
- 膽胰內視鏡(含子母鏡)
- 內視鏡膽胰取石術
- 內視鏡膽胰引流術(膽管癌、胰臟癌)
- 內視鏡超音波術
- 內視鏡超音波指引細胞抽取術
- 內視鏡胰偽囊腫引流術(慢性胰臟炎)
- 腹部超音波
- 腸胃道超音波



王秀伯

HSIU-PO WANG

## → 現任職務：

- 台大醫學院內科教授
- 台大醫院內視鏡科主任
- 台大醫院內科主治醫師
- 台灣內視鏡醫學會理事長
- 台灣胰臟醫學會理事
- 台灣消化系醫學會監事
- 台灣胰臟醫學會常務理事
- 台灣大腸直腸醫學會理事
- 台灣小腸醫學會常務理事

## → 主要學歷：

- 國立台灣大學醫學系畢業

## → 主要經歷：

- 台大醫院內科住院醫師1989~1992
- 台大醫院內科總醫師1992~1994
- 台大醫院急診醫學部及內科部主治醫師  
1994~2008/1
- 台大醫院內科部主治醫師2008/2~
- 日本京都赤十字病院研修1995

- 藤澤獎學金日本昭和大學國際內視鏡研修中心  
研修1998
- 台灣小腸疾病研究會發起人
- 台灣內科醫學會會員
- 台灣消化系醫學會會員
- 台灣消化系內視鏡醫學會會員
- 台灣胰臟醫學會會員
- 台灣急診醫學會會員
- 台灣急診加護醫學會會員
- 中華民國超音波醫學會會員
- 歐洲內視鏡醫學會會員
- 美國內視鏡醫學會會員

→ 過去成果：

- 每年多次受邀參加國際消化疾病及消化內視鏡  
演講及現場演示
- 舉辦多場國內外研討會
- 完成亞太膽胰內視鏡共識

→ 工作重點：

- 食道癌之診斷與治療
- 早期胃癌之內視鏡切除術
- 特殊光內視鏡術之應用
- 胰臟腫瘤治療計劃與分子生物學研究之整合
- 膽囊與膽道腫瘤之治療與分子生物學之整合
- 膽胰結石治療
- 慢性胰臟炎內視鏡治療
- 困難小腸疾病診治
- 消化急症超音波之應用



# 檢驗醫學部

搜尋 此網站

- [檢驗醫學部](#)
- [中文首頁](#)
- [歷史沿革](#)
- [組織架構](#)
- [檢驗醫學部臨床檢驗手冊](#)
- [文件下載](#)
- [聯絡我們](#)
- [English](#)

## 呂金盈 醫師

### 學歷：

- 臺灣大學醫學院臨床醫學研究所博士
- 臺灣大學醫學院醫學系學士

### 經歷：

- 臺灣大學醫學院附設醫院檢驗醫學部暨內科部內分泌新陳代謝科主治醫師
- 美國約翰霍普金斯醫學大學博士後研究

### 專長：

- 檢驗醫學
- 內分泌新陳代謝疾病
- 蛋白質轉譯後修飾及老化相關研究

### 主要研究領域：

- 蛋白質轉譯後修飾及老化相關研究

### [看診時間](#)



隱私權保護及資訊安全政策 | 醫療機構國際網路資訊管理辦法聲明：禁止任何國際網路服務業者轉錄本網路資訊之內容供人點閱。但以網路搜尋或超連結方式，進入本醫療機構之網

址(域)直接點閱者，不在此限。





- 簡介
- 門住診
- 衛生教育
- 診斷中心
- 睡眠醫學中心
- 高壓氧中心
- 肺復原運動
- 相關資訊

一般胸腔科

首頁 > 簡介 > 醫師介紹 > 一般胸腔科 > 賴信良醫師

- 陳育民主任
- 賴信良醫師**
- 趙恆勝醫師
- 陳威志醫師
- 周中偉醫師
- 蕭逸函醫師

賴信良醫師

A A A+



姓名：賴信良

專長：胸腔內科學、胸腔腫瘤學、肺癌的診斷與治療、標靶治療

現職：臺北榮民總醫院胸腔部 主治醫師

教職：教育部部定講師  
國防大學臨床教授

學歷：國立陽明大學臨床醫學研究所博士  
高雄醫學大學醫學士

經歷：臺北榮民總醫院胸腔部教學主任  
美國國立癌病研究院進修



◎ 最後更新：2017/09/01 10:56:32

臺北榮民總醫院 胸腔部  
地址：11217 台北市北投區石牌路二段201號  
總機：28712121  
傳真：2874-3466  
電子信箱：[cmd@vghtpe.gov.tw](mailto:cmd@vghtpe.gov.tw)

網站管理：資訊室  
本網站內容所有權歸臺北榮民總醫院所有，請尊重智慧財產權，未經允許請勿任意轉載、複製或做商業用途

目前在線人數：3 | 今日瀏覽人次：424 | 總瀏覽人次：

© Copyright 2015 by VGHTPE. All Rights Reserved.

369394



# CURRICULUM VITAE

**Chin-Yuan Tzen, MD, PhD**

**Chief Operating Officer**  
Kimforest Enterprise Co, Ltd

**Director**  
GeneOnLink Clinic

**President**  
Taiwanese Society of Molecular Medicine



## Office Address:

Kimforest Enterprise Co, Ltd  
30F, No 97, Sec 1, Xintai 5th Rd  
Xizhi Dist., New Taipei City  
Taiwan

Tel: (+886) 2-2697-6777 ext 168

e-mail: fjutzen@gmail.com

## Education:

Kaohsiung Medical College, Taiwan  
MD in Medicine, 1981  
Mayo Graduate School, Mayo Clinic, Rochester, MN  
Ph.D. in Experimental Pathology, 1989

## Certificate & License:

The American Board of Pathology (96-572)  
Tennessee Medical License (No. MD28109)  
Iowa Medical License (No. 30492)

## Membership:

College of American Pathologists (No. M-0704117)  
The International Society of Urological Pathology  
Taiwan Society of Pathology  
Taiwanese Society of Molecular Medicine

## Professional Experience:

1981-1983 Surgeon, Navy Service, Taiwan  
1983-1984 Resident, Department of Internal Medicine, Chang Gung Memorial Hospital, Taiwan  
1984-1985 Resident, Department of Pathology, Mackay Memorial Hospital, Taipei, Taiwan  
1985-1989 Graduate Student, Experimental Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA  
1989 Postdoctoral Fellow, Department of Molecular Biology and Biochemistry, Mayo Clinic, Rochester, Minnesota 55905, USA  
1989-1997 Assistant Professor, Department of Pathology, University of Tennessee, Memphis, Tennessee, USA  
1997-2001 Senior Pathologist, Department of Pathology, Mackay Memorial Hospital  
1999-2009 Director of Cancer Research, Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan  
2001-2009 Chairman, Department of Pathology, Mackay Memorial Hospital, Taipei, Taiwan  
2001-2009 Interstitial Review Board, Mackay Memorial Hospital, Taipei, Taiwan

2001-2009	IRB, Mackay Memorial Hospital
2005-2008	Director of Microbiology Research, Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
2006-2012	President, Taiwanese Society of Molecular Medicine
2009-2012	Consultant, Criminal Investigation Bureau, Taiwan
2010-2011	Committeeman, Advisory Committee (Medical Device), Food and Drug Administration, Ministry of Health, and Welfare, Taiwan
2011-2014	Examination Affairs Committee, Examination Yuan
2012-2013	Vice convenor, Safety Committee (Medical Device), T Food and Drug Administration, Ministry of Health, and Welfare
2012-2015	Managing Supervisor, Taiwanese Society of Molecular Medicine
2009-2017	Chairman, Department of Pathology and Laboratory Medicine, Cathay General Hospital
2009-2017	Director, Section of Molecular Medicine, Cathay General Hospital
2009-2017	Professor, College of Medicine, Fu Jen Catholic University
2011-2016	Vice convenor, Advisory Committee (Medical Device), Food and Drug Administration, Ministry of Health, and Welfare, Taiwan
2011-present	Consultant, Insurance Anti-fraud Institute, Executive Yuan, Taiwan
2013-2016	Committeeman, Safety Committee (Medical Device), Food and Drug Administration, Ministry of Health, and Welfare
2013-present	ISO 15189 Technical Inspector, Taiwan Accreditation Foundation
2013-present	ISO 17025 Technical Inspector, Taiwan Accreditation Foundation
2013-2016	Committeeman, GLP committee, Food and Drug Administration, Ministry of Health, and Welfare, Taiwan
2015-present	President, Taiwanese Society of Molecular Medicine
2017-present	Chief Operating Officer, Kimforest Enterprise Co, Ltd
2017-present	Director, GeneOnLink Clinic

#### **Invited lectures (International):**

1. The diagnostic standard of GIST in Taiwan (Bo'ao, Hainan Island, China; February 19, 2004)
2. Evolutional analysis in determining pathogenic versus nonpathogenic mutations of ATPase 6 in human mitochondriopathy (the 2nd conference of Asian Society for Mitochondrial Research and Medicine [ASMRM]; Taipei International Convention Center, Taipei, Taiwan; April 1, 2004)
3. View of a Pathologist – Management of a GIST Patient (JW Marriott Phuket Resort and SPA, Phuket, Thailand; May 5, 2004)
4. Evolving Role of Molecularly Targeted Therapy (Malaysian Oncological Society; Plenary Session; Hotel Istana, Kuala Lumpur, Malaysian; October 1, 2004)
5. Target Therapy without an apparent target: Can Imatinib be used in CD117-negative GIST? (Malaysian Oncological Society; Evening Symposium; Hotel Istana, Kuala Lumpur, Malaysian; October 1, 2004)
6. The target therapy without an apparent target: analysis of CD117-negative GISTs (The 11th Sino-Japan Symposium on Cancer Treatment; Taipei Veterans General Hospital, Taipei, Taiwan I; Oct. 9, 2004)
7. Recent findings and new insights in gastrointestinal stromal tumor (China Society of Pathology; Oversea Chinese Hotel, Guangzhou, China; Dec.23, 2004)
8. GIST in Asia Pacific and current issues in diagnosis (1st Meeting of the Asia Pacific GI Molecular Target Therapy Group; JW Marriott Hotel, Shanghai, China; January 21, 2005)
9. GIST/NET: where do we stand? (GI Forum; Hong Kong Society of Clinical Oncology and Hong Kong College of Radiologists; Grand Hyatt, Hong Kong; July 7, 2005)
10. GIST- where do we stand? (Pan Asia Pacific Oncology Summit, Prince Hotel, Chiba, Japan; July 9, 2005)
11. INTUIT Workshop, GIST-NET: from Diagnosis to Therapy (Regal International East Asia Hotel; Shanghai, China; August 20, 2005)
12. Mechanism and role of Mitochondrial mutation in human cancer (Mitochondria and life 2005, Toshi Center Hotel, Tokyo, Japan, December 16, 2005)
13. Molecular Basis and Clinical Implication of GIST (Optimizing Medical Management of GIST in the Imatinib Era; The Regent Singapore, Singapore; November 11, 2006)



**Yan Xuexian, MD, DABNM**

**颜学先 医学博士**



**Dr. Yan is currently a consultant physician with Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital and a visiting consultant with National Cancer Center Singapore.**

**Dr. Yan obtained his medical degree from Chongqing Medical University, China. He completed his residencies in internal medicine (Mount Sinai), nuclear medicine (Vanderbilt), and a clinical fellowship in PET/CT (Emory) in USA.**

**His postdoctoral oncology research fellowship was with Vanderbilt-Ingram Comprehensive Cancer Centre in Nashville, Tennessee, USA.**

**Before joining Singapore General Hospital, Dr. Yan was a faculty in division of nuclear medicine in Emory University Hospital and an attending radiologist in Trident Medical Imaging, both located in Atlanta, Georgia, USA.**

**Dr. Yan has strong interest in targeted radionuclide therapy such as PRRT for neuroendocrine tumors, PRLT for prostate cancer and SIRT for liver tumors.**

**Other than patient care, Dr. Yan is also devoted to medical education and research. He is an adj. assistant professor with Duke-NUS Medical School in Singapore.**



單位首頁 醫學院 網站地圖 English 成大首頁



#### 分類清單

最新消息  
 科部簡介  
 醫師介紹  
 次專科簡介  
 教學訓練  
 科內活動  
 相關連結  
 留言板

#### 沈延盛



教授/主治醫師 沈延盛

專長：膽胃腸道疾病、腫瘤外科、一般外科

姓名: 沈延盛 醫師

#### 主要學歷

畢業學校	科系所	學位	起訖年月
成功大學	臨床醫學研究所	博士	民國87年9月~民國93年6月
成功大學	醫學院學士後醫學系	醫學士	民國77年9月~民國82年6月

現職: 外科部及臨床醫學研究所教授

服務機關	服務部門	職稱	起訖年月
成功大學附設醫院	臨床研究中心	主任	105年8月
成功大學附設醫院	外科部	教授兼外傷科主任	民國101年8月~
成功大學附設醫院	腫瘤中心上消化道癌症	召集人	民國99年8月

#### 經歷

服務機關	服務部門	職稱	起訖年月
成功大學附設醫院	外科部	副教授兼外傷科主任	民國99年9月~民國101年8月
成功大學醫學院	臨床醫學研究所	副教授	民國99年8月~民國101年7月
成功大學醫學院	外科部	副教授	民國99年8月~民國101年7月
成功大學醫學院	外科部	兼任副教授	民國97年8月~民國98年7月

#### 專長

臨床	肝膽胰外及胃腸腫瘤外科學, 外科營養學, 外科感染學, 胃腸生理學
研究	肝胰再生醫學, 腫瘤學(腫瘤微環境的研究: 癌幹細胞, 腫瘤相關免疫細胞及腫瘤相關纖維)

細胞的交互作用), 胃腸基質瘤轉移的機轉, 靜脈及腸道營養在術後的應用

學術論文 (Selected publications since 2010)

1. Chang-Ni Lin, Hui-Ling Tung, Ming-Derg Lai, and Yan-Shen Shan\*. Gastric Cancer Cells Promote Tumorigenesis by Signaling M2-Macrophages via Osteopontin. 2013 (submitted)
2. Ying-Jui Chao, Chih-Jung Wang, Yan-Shen Shan\*. The Impact of Tumor Size in Laparoscopic Spleen and Splenic Vessels Preserving Distal Pancreatectomy. 2013 (submitted)
3. Ming-Chen Yang, Huan-Yao Lei, Yan-Wei Wu, Yan-Shen Shan\*, and Pin-Wen Lin. Autophagy regulates pancreatic cancer stem cell activity. *Autophagy* 2013 (revision)
4. Chih-Jung Wang, Ying-Jui Chao, Yan-Shen Shan\*, Pin-Wen Lin. Simultaneous Splenectomy Accelerates Liver Regeneration after Major Hepatectomy in Rats via Decreasing Activin-A Expression. *Liver International* 2013 (revision)
5. Ying-Jui Chao, Edgar D Sy, Kai-Hsi Hsu, Hui-Ping Hsu, Yan-Shen Shan\*. Predictors for Resectability and Survival in Locally Advanced Pancreatic Cancer after Gemcitabine-based Neoadjuvant Therapy. 2013 (Submitted)
6. Chin-Wong Chen, Hui-Ling Dong, Chang-Ni Lin, Yi-Ling Chen, Da-Bin Hsieh, Yan-Shen Shan\*. Loss of Gelsolin Expression by Epigenetic Alteration Related with Progression of Gastric Cancer. (submitted)
7. Hsin-Hsien Yu, Yan-Shen Shan\*. Duodenal-jejunal Bypass Can Reduce Non-alcoholic Steatohepatitis via Modulation of Insulin Sensitivity and Activity of Hepatic Stellate Cells. *Obese Surg* 2013 (revision)
8. Andrew H. Ko, Margaret A. Tempero, Yan-Shen Shan, Wu-Chou Su, Yu-Lin Lin, Elizabeth Dito, Anna Ong, Yi-Wen Wang, C. Grace Yeh, Li-Tzong Chen. A Multinational Phase 2 Study of Nanoliposomal Irinotecan (PEP02, MM-398) for Patients with Gemcitabine-refractory Metastatic Pancreatic Cancer. *BJC* 2013 (accepted)
9. Chen CW, Ming CC, Ma CJ, Shan YS, Yeh YS, Wang JY. Prospective, Randomized, Study of Ampicillin-Sulbactam versus Moxifloxacin Monotherapy for the Treatment of Community-Acquired Complicated Intra-Abdominal Infections. *Surg Infect (Larchmt)*. 2013 Jul 16. [Epub ahead of print]
10. Hsueh YS, Lin CL, Chiang NJ, Yen CC, Li CF, Shan YS, Ko CH, Shih NY, Wang LM, Chen TS, Chen LT. Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations. *PLoS One*. 2013 Jun 20; 8(6):e65762.
11. Cheng HC, Liu YP, Shan YS, Huang CY, Lin FC, Lin LC, Lee L, Tsai CH, Hsiao M, Lu PJ. Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer. *Carcinogenesis*. 2013 Jul 8. [Epub ahead of print]
12. Su CC, Lin HC, Lin YP, Shan YS, Yang BC. Expression of Th17-related genes in PHA/IL-2-activated human T cells by Fas signaling via caspase-1- and Stat3-dependent pathway. *Cell Immunol*. 2013 Feb;281(2):101-10.
13. Chen YP, Hung LY, Shan YS, Chang KC. ALK-positive large B-cell lymphoma presenting with jejunal intussusception. *Eur J Haematol*. 2013 Mar;90(3):261.
14. Chao YJ, Shan YS\*, Zuchini R, Tsai HW, Lin PW, Lee GB, Lin XZ. Successfully seal pancreatic end after thermal distal pancreatectomy using needle arrays in alternating electromagnetic fields. *Surg Innov*. 2013 Apr;20(2):150-7.
15. Ying-Jui Chao, Chih-Jung Wang, Yan-Shen Shan\*. A Self-designed, Simple, Secure, and Safe 6-loop Intracorporeal Pringle's Maneuver for Laparoscopic Liver Resection. *Surg Endosc* 2012 Sep; 26(9): 2681-6.
16. Vincent H. S. Chang, Pei-Yi Chu, Shu-Ling Peng, Tsui-Lien Mao, Yan-Shen Shan, Ching-Fang Hsu, Chun-Yu Lin, Kelvin K.C. Tsai, Winston C. Y. Yu, Hui-Ju Chang. Kruppel-like factor 10 Expression as a Prognostic Indicator for Pancreatic Adenocarcinoma. *Am J Pathol* 2012 Aug;181(2):423-30.
17. Tseng PC, Huang WC, Chen CL, Sheu BS, Shan YS, Tsai CC, Wang CY, Chen SO, Hsieh CY, Lin CF. Regulation of SHP2 by PTEN/AKT/GSK-3 $\beta$  signaling facilitates IFN- $\gamma$  resistance in hyperproliferating gastric cancer. *Immunobiology*. 2012 Sep;217(9):926-34.
18. Huang SC, Chang YY, Chao YJ, Shan YS, Lin XZ, Lee GB. Dual-row needle arrays under an electromagnetic thermotherapy system for bloodless liver resection surgery. *IEEE Trans Biomed Eng*. 2012 Mar; 59(3): 824-31.
19. Lin FC, Liu YP, Lai CH, Shan YS, Cheng HC, Hsu PI, Lee CH, Lee YC, Wang HY, Wang CH, Cheng JQ, Hsiao M, Lu PJ. RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. *Oncogene* 2012;31(39):4302-16.
20. Hsin-Hsien Yu, Ta-Ming Yang, Yan-Shen Shan\*, Pin-Wen Lin. Zinc Deficiency in Patients Received Pancreatoduodenectomy is Associated with Pancreatic Exocrine Insufficiency *World J Surg* 2011 Sep; 35(9): 2110-7.

21. Yan-Shen Shan, Jung-Hua Fang, Ming-Derg Lai, Meng-Chi Yen, Pin-Wen Lin, Hui-Ping Hsu, Chian-Yun Lin, Yi-Ling Chen. Establishment of an orthotopic transplantable gastric cancer animal model for studying the immunological effects of new cancer therapeutic modules. *Mol Carcinogenesis* 2011 Oct;50(10):739-50.
22. Kai-Hsi Hsu, Hung-Wen Tsai, Pin-Wen Lin, Yun-Shang Hsu, Yan-Shen Shan\*, and Pei-Jung Lu\*. Clinical Implication and Mitotic Effect of CD44 Cleavage in Relation to Osteopontin/CD44 Interaction and Dysregulated Cell Cycle Protein in Gastrointestinal Stromal Tumor. *Ann Surg Oncol* 2010; 17(8): 2199-212.
23. Kai-Hsi Hsu, Hung-Wen Tsai, Pin-Wen Lin, Yun-Shang Hsu, Pei-Jung Lu\*, and Yan-Shen Shan\*. Osteopontin Expression is an Independent Adverse Prognostic Factor in Resectable Gastrointestinal Stromal Tumor and its Interaction with CD44 Promotes Tumor Proliferation. *Ann Surg Oncol* 2010; 17(11):3043-52.
24. Hsin-Hsien Yu, Yan-Shen Shan\*, Pin-Wen Lin. Effect of Pancreatoduodenectomy on the Course of Hepatic Steatosis *World J Surg* 2010; 34(9):2122-7.
25. Ch'ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study. *Int J Radiat Oncol Biol Phys.* 2011 Dec 1;81(5):e749-57.
26. Lin SC, Shan YS\*, Lin PW. Adequate preoperative biliary drainage is determinative to decrease postoperative infectious complications after pancreaticoduodenectomy. *Hepatogastroenterology.* 2010 Jul-Aug;57(101):698-705.
27. Shan YS, Zucchini R, Tsai HW, Lin PW, Lee GB, Lin XZ. Bloodless liver resection using needle arrays under alternating electromagnetic fields. *Surg Innov.* 2010 Jun;17(2):95-100.
28. Hsu HP, Shan YS, Lai MD, Lin PW. Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival. *Cancer Biol Ther.* 2010 Jul 15;10(2):144-54.
29. Hsu HP, Shan YS, Jin YT, Lai MD, Lin PW. Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms. *J Surg Oncol.* 2010 Apr 1;101(5):356-62.

瀏覽數 11150

[轉寄親友](#) [友善列印](#) [新增到收藏夾](#) [分享](#)

您覺得這篇文章有幫助嗎?

總共投票數:0 平均得分:0

[我來投票](#)

# Curriculum Vitae

**Name:** Chou, Wen-Chi (周文其)

**EDUCATION:** 1993-2000 Medical Degree, Taipei Medical College, Taipei, Taiwan

## **EMPLOYMENT RECORD:**

2000/07 ~ 2005/06	林口長庚內科部住院醫師及總醫師
2005/07 ~ 2006/10	林口長庚醫院血液腫瘤科主治醫師
2006/12 ~ 2010/12	桃園聖保祿醫院腫瘤科主治醫師
2008/09 ~ 2010/06	輔仁大學醫學系兼任講師
2012/07 ~ 2016/06	林口長庚醫院助理教授
2016/07 ~ 迄今	林口長庚醫院副教授

## **PROFESSIONAL AFFILIATIONS:**

Society of Internal Medicine, R.O.C.  
The Chinese Oncology Society, R.O.C.  
Society of Palliative Medicine, R.O.C.  
Taiwan Society of Cancer Palliative Medicine, R.O.C.

## **BIBLIOGRAPHY:**

### *Publications associated with neuroendocrine tumor*

1. **Chou WC**, Hung YS, Hsu JT\*, Chen JS, Lu CH, Hwan TL, Rau KM, Yeh KY, Chen TC, Sun CF. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. *Neuroendocrinology*. 2012; 95:344-350.
2. **Chou WC**, Chen JS, Hung YS, Hsu JT, Chen TC, Sun CF, Lu CH, Hwang TL\*. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors. *Anticancer Res*. 2014 ; 34(10) :5661-5669.
3. Liu CT, Chen MH, Chen JS, Chen LT, Shan YS, Lu CH, Su YL, Ku FC, **Chou WC**\*, Chen YY. The efficacy and safety of everolimus for the treatment of progressive gastroentero- pancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. *Asia Pac J Clin Oncol*. 2016;12(4):396-402.
4. **Chou WC**, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, Li CP, Chao Y, Chen MH\*. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. *Int J Biol Sci*. 2016;12(12):1523-1532.
5. Chen SH, Chang YC, Hwang TL, Chen JS, **Chou WC**, Hsieh CH, Yeh TS, Hsu JT, Yeh CN, Tseng JH, Chen TC, Yen TC. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan. *J Formos Med Assoc*. 2017 Jul 20. doi: 10.1016/j.jfma.2017.07.007.



## **Dr James Yao**

Professor with Tenure, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

---

### **Present Title & Affiliation**

Professor with Tenure, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

---

### **Education & Training**

#### Degree-Granting Education

1995     Baylor College of Medicine, Houston, TX, USA, MD, Medicine

1991     Rice University, Houston, TX, USA, BA, Computer Science

#### Postgraduate Training

1998-2001     Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

---

### **Board Certifications**

2003     Board Certification in Medical Oncology (ABIM)

1999     Board Certification in Internal Medicine (ABIM)

---

### **Experience & Service**

#### *Academic Appointments*

Associate Professor with Tenure, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2013

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2009

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, M. D. Anderson Cancer Center, Houston, TX, 2001 - 2007

### Administrative Appointments/Responsibilities

Department Chair, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present

Deputy Department Chair, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2015

Faculty Supervisor of Mid-Level Providers Program, The University of Texas MD Anderson Cancer Center Department of Gastrointestinal Medical Oncology, Houston, TX, 2003 - Present

### *Institutional Committee Activities*

Internal Member, Vice Provost Advisory Council - Clinical Research, 2014 - Present

Member, Executive Core Committee for Electronic Health Record, 2013 - Present

Member, Multidisciplinary Research Advisory Committee, 2013 - Present

Principal Investigator, Phase II Contract (N01) Committee, 2011 - Present

Member, Personalized Risk Prediction Program of Duncan Family Institute Steering Committee, 2010 - Present

Member, Clinical Research Program Executive Steering Committee, 2009 - Present

Member, Research and Education Information System Steering Team, 2009 - Present

Co-Chairman, Enterprise Internet Strategy Steering Team (EISST) Physician and Scientist Workgroup, 2008 - Present

Member, Phase II Contract (N01) Committee, 2006 - 2011

Member, Southwest Oncology Group (SWOG) Executive Committee, 2006 - 2012

---

### **Honors & Awards**

2012 The Murray Brennan Distinguished Lecturer, Memorial Sloan-Kettering Cancer Center

2011 Irwin H. Krakoff Excellence in Clinical Research Award, U.T. MD Anderson Cancer Center

2009 Distinguished Alumni Award, U.T. MD Anderson Cancer Center